The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

Cd55  -  CD55 antigen

Mus musculus

Synonyms: Cd55a, Complement decay-accelerating factor, GPI-anchored, Cromer blood group, DAF-GPI, Daf, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Cd55

  • Compared with wild-type mice, Daf1(-/-) mice also displayed markedly exacerbated disease progression and pathology in a T cell-dependent experimental autoimmune encephalomyelitis (EAE) model [1].
  • Baseline albuminuria in the Daf1(-/-), CD59a(-/-), and Daf1(-/-)CD59a(-/-) mice was 82, 83, and 139 as compared with 92 microg/mg creatinine in the WT controls (p > 0.1) [2].
  • We induced nephrotoxic serum (NTS) nephritis in Daf1(-/-), CD59a(-/-), Daf1(-/-)CD59a(-/-), and wild-type (WT) mice by administering NTS IgG [2].
  • Seven days after consuming 3% dextran sulfate sodium in their drinking water, Daf1(-/-) mice suffered markedly greater weight loss (-24.7 +/- 7.5% vs -14.2% +/- 4.9%), exhibited uniformly bloody diarrhea as compared with soft stool in control mice, developed shortened colons, and had larger spleens [3].

High impact information on Cd55


Biological context of Cd55


Anatomical context of Cd55


Associations of Cd55 with chemical compounds

  • This contrasted with marked deposition of both C3 and C9 in Daf1(-/-)CD59a(-/-) and Daf1(-/-) mice, which was evident as early as 2 h post-NTS injection [2].
  • Furthermore, the regulation of uterine DAF expression by estrogen is limited to the GPI DAF gene [9].

Other interactions of Cd55

  • In mice, both GPI-anchored and transmembrane-anchored DAF proteins are produced, each of which can be derived from two different genes (Daf1 and Daf2) [8].

Analytical, diagnostic and therapeutic context of Cd55

  • Electron microscopy demonstrated markedly greater junctional damage in the Daf1(-/-) mice compared with the Daf1(+/+) littermates [10].
  • Molecular cloning of mouse decay accelerating factor (DAF; CD55) predicted two forms of the molecule, one transmembrane (TM) and the other glycosylphosphatidylinositol (GPI)-anchored; these are encoded by separate genes termed Daf-GPI and Daf-TM [11].
  • Northern blot analysis indicated that rat GPI-DAF mRNA was present in all tissues examined except for liver, while rat TM-DAF mRNA was preferentially expressed in testis [12].
  • At 48h, Daf1(-/-) were significantly weaker than CD59a(-/-) and WT mice, and for these mice immunohistochemistry revealed marked C9 deposition at postsynaptic junctions, radioimmunoassays showed reductions in AChR levels, and electron microscopy demonstrated massive junctional damage [13].


  1. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. Liu, J., Miwa, T., Hilliard, B., Chen, Y., Lambris, J.D., Wells, A.D., Song, W.C. J. Exp. Med. (2005) [Pubmed]
  2. Respective roles of decay-accelerating factor and CD59 in circumventing glomerular injury in acute nephrotoxic serum nephritis. Lin, F., Salant, D.J., Meyerson, H., Emancipator, S., Morgan, B.P., Medof, M.E. J. Immunol. (2004) [Pubmed]
  3. Decay-accelerating factor deficiency increases susceptibility to dextran sulfate sodium-induced colitis: role for complement in inflammatory bowel disease. Lin, F., Spencer, D., Hatala, D.A., Levine, A.D., Medof, M.E. J. Immunol. (2004) [Pubmed]
  4. Molecular basis of reduced or absent expression of decay-accelerating factor in Cromer blood group phenotypes. Lublin, D.M., Mallinson, G., Poole, J., Reid, M.E., Thompson, E.S., Ferdman, B.R., Telen, M.J., Anstee, D.J., Tanner, M.J. Blood (1994) [Pubmed]
  5. Constitutive expression of murine decay-accelerating factor 1 is controlled by the transcription factor sp1. Cauvi, D.M., Cauvi, G., Pollard, K.M. J. Immunol. (2006) [Pubmed]
  6. Characterization of glycosylphosphatidylinositol-anchored decay accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity. Miwa, T., Sun, X., Ohta, R., Okada, N., Harris, C.L., Morgan, B.P., Song, W.C. Immunology (2001) [Pubmed]
  7. Decay-accelerating factor confers protection against complement-mediated podocyte injury in acute nephrotoxic nephritis. Lin, F., Emancipator, S.N., Salant, D.J., Medof, M.E. Lab. Invest. (2002) [Pubmed]
  8. Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies. Lin, F., Fukuoka, Y., Spicer, A., Ohta, R., Okada, N., Harris, C.L., Emancipator, S.N., Medof, M.E. Immunology (2001) [Pubmed]
  9. Mouse decay-accelerating factor: selective and tissue-specific induction by estrogen of the gene encoding the glycosylphosphatidylinositol-anchored form. Song, W.C., Deng, C., Raszmann, K., Moore, R., Newbold, R., McLachlan, J.A., Negishi, M. J. Immunol. (1996) [Pubmed]
  10. Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. Lin, F., Kaminski, H.J., Conti-Fine, B.M., Wang, W., Richmonds, C., Medof, M.E. J. Clin. Invest. (2002) [Pubmed]
  11. Molecular and functional analysis of mouse decay accelerating factor (CD55). Harris, C.L., Rushmere, N.K., Morgan, B.P. Biochem. J. (1999) [Pubmed]
  12. Alternative exon usage in the 3' region of a single gene generates glycosylphosphatidylinositol-anchored and transmembrane forms of rat decay-accelerating factor. Miwa, T., Okada, N., Okada, H. Immunogenetics (2000) [Pubmed]
  13. Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia. Kaminski, H.J., Kusner, L.L., Richmonds, C., Medof, M.E., Lin, F. Exp. Neurol. (2006) [Pubmed]
WikiGenes - Universities